VRC-07-523
- Generic Name
- VRC-07-523
Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2025-01-30
- Target Recruit Count
- 48
- Registration Number
- NCT06517693
- Locations
- 🇵🇷
Site 5129, IMPAACT/Gamma Project/UPR Pediatric HIV/AIDS Research, San Juan, Puerto Rico
🇺🇸Site 5030, Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Site 5112, David Geffen School of Medicine at UCLA, Los Angeles, California, United States
The Tatelo Plus Study
- Conditions
- HIVHIV Infections
- Interventions
- Other: Analytic Treatment InterruptionDrug: ART Regimen prior to enrolling in Step 1aDrug: ART Regimen prior to enrolling in Step 1b
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-11-20
- Target Recruit Count
- 41
- Registration Number
- NCT06508749
- Locations
- 🇧🇼
Francistown CRS (CRS #31891), Francistown, Botswana
🇧🇼Botswana Harvard Health Partnership CRS (CRS #31833), Gaborone, Botswana
RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV
- Conditions
- Acute HIV InfectionHIV InfectionsPLWHART
- Interventions
- Biological: VRC07-523LSBiological: PGDM1400LSOther: PlaceboBiological: ChAdOx1.tHIVconsv1Biological: ChAdOx1.HIVconsv62Biological: MVA.tHIVconsv4Biological: A244d11 gp120Biological: ALFQ
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Target Recruit Count
- 48
- Registration Number
- NCT06484335
- Locations
- 🇹ðŸ‡
The Faculty of Medicine, Chulalongkorn University/ King Chulalongkorn Memorial Hospital, Pathum Wan, Bangkok, Thailand
10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults
- Conditions
- HIV-1-infection
- Interventions
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- David Ho
- Target Recruit Count
- 20
- Registration Number
- NCT05890963
- Locations
- 🇹🇿
National Institute for Medical Research-Mbeya Medical Resarch Center, Mbeya, Tanzania
A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission
- Conditions
- Acute HIV Infection
- Interventions
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2025-04-23
- Target Recruit Count
- 48
- Registration Number
- NCT05719441
- Locations
- 🇺🇸
31788, Alabama CRS, Birmingham, Alabama, United States
🇺🇸1201, University of Southern California CRS, Los Angeles, California, United States
🇺🇸601, University of California, Los Angeles CARE Center CRS, Los Angeles, California, United States
Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults
- Conditions
- Acquired Immunodeficiency SyndromeImmunologic Deficiency Syndrome, AcquiredHIVSexually Transmitted Diseases, ViralRetroviridae Infections
- Interventions
- Biological: MVA-BN-HIV
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Boris Juelg, MD PhD
- Target Recruit Count
- 36
- Registration Number
- NCT04983030
- Locations
- 🇺🇸
UCLA CARE (Center for AIDs Research and Education), Los Angeles, California, United States
🇺🇸Orlando Immunology Center, Orlando, Florida, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption
- Conditions
- HIV Infection
- Interventions
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2025-03-25
- Target Recruit Count
- 118
- Registration Number
- NCT04340596
- Locations
- 🇺🇸
New Jersey Medical School Clinical Research Center CRS [Site ID: 31786], Newark, New Jersey, United States
🇺🇸Columbia P&S CRS, New York, New York, United States
🇺🇸Weill Cornell Uptown CRS (Site ID: 7803), New York, New York, United States
Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2024-12-13
- Target Recruit Count
- 33
- Registration Number
- NCT04212091
- Locations
- 🇺🇸
George Washington Univ. CRS, Washington, District of Columbia, United States
🇺🇸Columbia P&S CRS, New York, New York, United States
🇺🇸The Hope Clinic of the Emory Vaccine Center CRS, Decatur, Georgia, United States
Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1
- Conditions
- HIV Infections
- Interventions
- Drug: Nucleoside Reverse Transcriptase Inhibitors (NRTIs)Drug: Standard of Care (SOC) Oral ART
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2024-11-22
- Target Recruit Count
- 75
- Registration Number
- NCT03739996
- Locations
- 🇺🇸
Johns Hopkins University CRS, Baltimore, Maryland, United States
🇵🇷Puerto Rico AIDS Clinical Trials Unit CRS, San Juan, Puerto Rico
🇺🇸UCSD Antiviral Research Center CRS, San Diego, California, United States
Evaluating the Safety and Pharmacokinetics of VRC07-523LS in the Sera and Mucosae of Healthy, HIV-Uninfected Adult Participants
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2025-05-15
- Target Recruit Count
- 28
- Registration Number
- NCT03735849
- Locations
- 🇺🇸
Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston, Massachusetts, United States
🇺🇸Seattle Vaccine and Prevention CRS, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.